Geron's novel method reduces number of steps, cost in synthesizing monomer building blocks

By Lisa Kerner

Charlotte, N.C., July 13 - Geron Corp. said its novel chemical method reduces the number of chemical steps and cost of synthesizing the monomer building blocks of its patented N3'-P5' thiophosphoramidate oligonucleotide compounds.

The method uses starting materials containing a nitrogen in the key (3') position, reducing the number of steps to achieve the final activated 3'-amino monomer building blocks from seven-ten to two-three.

Geron presented its method in a paper published in the June 26 issue of Tetrahedron Letters.

"Our lead anticancer drug, GRN163L, which is in clinical trials for hematologic and solid tumor malignancies, is now being manufactured using the new chemistry monomers," vice president of oncology Melissa A. Kelly Behrs said in a company news release.

Geron is a Menlo Park, Calif.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.